|
|
 |
Home : Info Center
Information Resource Center
Press Releases
- DiaKine Therapeutics and Kinexum Metabolics to Develop Novel Combination Treatment to Type 1 Diabetes
- Kinexum Metabolics, Inc. Announces Abstracts on INGAP Peptide Will Be Presented at Keystone Symposia
- Kinexum Metabolics, Inc. Announces Peter Damsbo, M.D. Joins Clinical Development Team for INGAP Peptide
- McGill University Health Centre Announces Important Support for Advancing INGAP as a Therapy for Type 1 Diabetes
- Zoe Heineman Myers expands Kinexum's expertise
in the diabetes sector.
- Dr. G. Alexander Fleming, Kinexum CEO, to speak at Metabolic Summit November
1-2 in San Diego, California. Generating β-cells in TI and T2
Diabetes
Mellitus—a Promising Therapeutic Target and Plenary Lecture: The
Future Regulatory Environment for Metabolic Drugs—Sorting through
the Good, the Bad, and the Ugly. For more information and to register – [Link]
September 30, 2007
- Dr. G. Alexander Fleming, Kinexum CEO, to speak at education conference November 29-30 in Alexandria, Virginia. Pipeline to Product – Navigating the FDA Approval Process.
For more information and to register – [Link],
September 21, 2007
-
Generex Biotechnology Engages Kinexum to Bolster Clinical and Regulatory Areas, December 18, 2003
Presentations (PowerPoint)
Books
Selected Papers, Documents, Articles
- C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve ß-Cell Function, Jerry P. Palmer, G. Alexander Fleming, Lisa D. Jansa, et al, Diabetes 53(1), Jan 2004, p. 250-264
- A Task and Problem Focused Approach to the Development and Regulation of Drugs, G. Alexander Fleming, MD (PDF file)
- Zan Fleming Leaves Improved CDER Seminars as Legacy, News Along the Pike, August 1998
Copyright © 2004 Kinexum LLC | terms of use | privacy
|
|
|
